Clinical Trials Sponsored by The Emmes Company, LLC

Total 160 results

National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
Duke University
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075 (Pharm-OUD-Care)

Opioid Use Disorder

United States
Sanotize Research and Development corp.
The Emmes Company, LLC; Keyrus Life Science

Completed

Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection (NOCOVID)

Corona Virus Infection

Canada
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC; Inovio Pharmaceuticals

Active, not recruiting

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Anal Intraepithelial Neoplasia | High Grade Squamous Intraepithelial Neoplasia | HIV Positivity | Human Papillomavirus-16 Positive | Human Papillomavirus-18 Positive

United States, Puerto Rico
NYU Langone Health
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Opioid Use Disorder

United States
Nova Immunotherapeutics Limited
The Emmes Company, LLC; Nova Laboratories Limited; Mercia Pharma Inc.

Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (MER4101)

Influenza, Human

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC; PTC Therapeutics

Terminated

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Kaposi's Sarcoma

United States
Joshua M Hare
The Emmes Company, LLC; The Lester And Sue Smith Foundation

Terminated

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) (AETHER)

Idiopathic Pulmonary Fibrosis (IPF)

United States
Hennepin Healthcare Research Institute
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Recruiting

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy (EXHITENTRE)

Substance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe

United States
Stanford University
National Institute of Neurological Disorders and Stroke (NINDS); The Emmes...

Completed

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) (MONEAD)

Epilepsy | Pregnancy

United States
Hennepin Healthcare Research Institute
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Recruiting

EXHIT ENTRE Comparative Effectiveness Trial (EXHITENTRE)

Substance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe

United States
Kanecia Obie Zimmerman
National Institutes of Health (NIH); The Emmes Company, LLC

Completed

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01)

Infantile Hemangioma

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Active, not recruiting

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

HIV Infection | Anal Intraepithelial Neoplasia | High-grade Squamous Intraepithelial Lesion

United States, Puerto Rico
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Completed

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

AIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Diffuse Mixed Cell Lymphoma | AIDS-related Diffuse Small Cleaved Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Lymphoblastic Lymphoma | AIDS-related Small Noncleaved... and other conditions

Zimbabwe, Kenya
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Completed

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Precancerous Condition | Anal Cancer | Nonneoplastic Condition | Neoplasm of Uncertain Malignant Potential

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Completed

Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America

HIV Infection | Malignant Neoplasm | Recurrent Malignant Neoplasm | Human Immunodeficiency Virus 1 Positive

Mexico, Argentina, Brazil
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Terminated

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

HIV Infection | Unspecified Adult Solid Tumor, Protocol Specific | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult... and other conditions

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Completed

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

HIV Infection | Precancerous Condition | Malignant Neoplasm

United States
University of Miami
National Heart, Lung, and Blood Institute (NHLBI); The Emmes Company, LLC

Completed

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

Stem Cell Transplantation

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

Macular Disease | Retinal Disease

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Ranibizumab and Bevacizumab for Diabetic Macular Edema

Diabetic Macular Edema

United States, United Kingdom
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Dextromethorphan for Diabetic Macular Edema (MiDME2)

Diabetic Macular Edema

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Terminated

Finasteride for Chronic Central Serous Chorioretinopathy

Retinal Disease

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Cocaine Use Reduction With Buprenorphine (CURB)

Cocaine Dependence

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis

Uveitis

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

Immunosuppression | Anterior Uveitis | Arthritis, Juvenile Idiopathic | Iritis

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

Retinitis Pigmentosa

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone (SWIFT)

Opioid-use Disorder

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Gevokizumab for Active Scleritis

Scleritis

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Terminated

A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients (GVHD ASED)

Graft vs Host Disease

United States
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema

Diabetic Macular Edema

United States
University of Texas Southwestern Medical Center
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder (ADAPT-2)

Methamphetamine Use Disorder

United States
Eunice Kennedy Shriver National Institute of Child...
The Emmes Company, LLC

Completed

Lorazepam for the Treatment of Status Epilepticus in Children

Status Epilepticus

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; The...

Completed

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

Human Immunodeficiency Virus | High Grade Anal Canal Squamous Intraepithelial Neoplasia

United States
Lindell Weaver
U.S. Army Medical Research and Development Command; The Emmes Company, LLC; Intermountain... and other collaborators

Completed

Normative Datasets for Assessments Planned for Mild Traumatic Brain Injury (NORMAL) (NORMAL)

Focus: Healthy Adults Without Brain Injury

United States
Anne Lindblad
National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil...

Completed

NINDS CRC Chronic Migraine Treatment Trial (CMTT)

Chronic Migraine

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (MOMs-INO)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Neonatal Opiate Withdrawal Syndrome | Drug Abuse in Pregnancy

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Active, not recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal Syndrome

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); Montefiore Medical Center; University of Arkansas and other collaborators

Completed

Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer

Acquired Immunodeficiency Syndrome | Cervical Cancer

South Africa, Zimbabwe
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; University of Stellenbosch

Withdrawn

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

HIV Infection | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | FIGO Stage IIB Cervix Carcinoma | FIGO Stage III Cervix Carcinoma | FIGO Stage IVA Cervix Carcinoma

South Africa, Zimbabwe
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC; US Military HIV Research Program

Completed

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Hemorrhagic Fever, Ebola

Uganda
Mayo Clinic
The Patient Company, LLC

Recruiting

A Study to Evaluate SimPull for Lateral Patient Transfer

Lateral Patient Transfer

United States
Columbia University
National Institute on Drug Abuse (NIDA); University of Miami; Emory University; The Emmes Company, LLC

Recruiting

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients (CTN0121)

Substance Use Disorders | Injection Site Infection

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; Vasgene Therapeutics, Inc

Recruiting

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Skin Kaposi Sarcoma

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Active, not recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (MOMs-CMA)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal Syndrome

United States
David Ho
Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative; The...

Completed

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

HIV-1-infection

United States
Boston Children's Hospital
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC; Friends Research...

Completed

Adolescent SCreening To Help Eliminate Misuse (ASC-THEM)

Substance Use

United States
The Emmes Company, LLC
National Eye Institute (NEI); University of Wisconsin, Madison; Milton S. Hershey...

Completed

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) (SCORE2)

Central Retinal Vein Occlusion

United States
Walter Ling
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT)

Methamphetamine Use Disorder

United States

Clinical Trials Sponsored by The Emmes Company, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations